Spherix Global Insights finds doctors have yet to define where APT-1011 will sit in the treatment path relative to EoE
US neurologists in Spherix’s in-house physician network complete a patient chart audit of over 600 patients with gMG. Exton, PA,
According to Spherix Global Insights first market landscape study on Amyotrophic Lateral Sclerosis (ALS), general neurologists lack awareness of therapies
According to Spherix Global Insights, U.S. neurologists are largely satisfied with current treatment choices in the RMS market, but opportunities remain.
Prospects for Syfovre uptake and trust in Apellis take a plunge following reports of intraocular inflammation, according to Spherix Global
According to Spherix Global Insights, US Rheumatologists are taking increasing ownership over lupus nephritis (LN) patient management, yet they are
As fatty liver disease gets a new name, will it also finally get approved drug treatments? That’s what healthcare professionals
According to Spherix Global Insights and EU5 nephrologists are anticipating a more dynamic and competitive HIF-PH inhibitor market Exton, PA,
Spherix Global Insights finds gastroenterologist and hepatologist capacity is being stretched to the limit by increasing demand from MASLD/MASH patients
After early adoption, overall use of Olumiant in alopecia areata is beginning to level-off, according to Spherix Global Insights Exton,
Lack of vision improvement, amongst other efficacy concerns, as well as potential for conversion to neovascular age-related macular degeneration are
Uptake and user-base of Byooviz (Biogen) and Cimerli (Coherus) have both been low while general attitudes around biosimilars seem to
